

SCHNADER HARRISON SEGAL & LEWIS  
INTELLECTUAL PROPERTY DEPARTMENT  
36th Floor  
1600 Market Street  
Philadelphia, PA 19103

u Pe

TELEPHONE (215) 563-1810  
FACSIMILE (215) 568-6946 OR (215) 564-2535  
PROCOMM PLUS (215) 563-8220

FAX RECEIVED

FACSIMILE TRANSMITTAL

FEB 12 2002

To: Examiner Ron Schwadron, Art Unit 1644

GROUP 1600

Company: USPTO

Facsimile No.: 703-308-4242

From: T. Daniel Christenbury, Reg. No. 31,750

OFFICIAL

Date: February 12, 2002

Re: USSN 09/155,514

Docket No.: 1102-98

Number of Pages (including cover page): 11

If you do not receive all the pages or experience any difficulty receiving this transmission, please call (215) 563-1810.

Additional Instructions/Comments:

Dear Examiner Schwadron:

Pursuant to a discussion with my secretary today, I am faxing herewith a copy of the Amendment submitted to the USPTO on January 14, 2002. This is a courtesy copy only since the originally filed version has not yet been matched with the file.

I look forward to your next action and remain, with kindest regards.

Respectfully submitted,

  
T. Daniel Christenbury  
Reg. No. 31,750

TDC:rb  
(215) 563-1810

Attorney Docket No.: 1102-98

In re Application of: Mie Kainoh et al.

Serial No.: 09/155,514

Filed: November 17, 1998

For: CHIMERIC PROTEINS, THEIR HETERO DIMER COMPLEXES, AND PLATELET SUBSTITUTES

Box AF  
 COMMISSIONER FOR PATENTS  
 Washington, DC 20231

Sir:

Transmitted herewith is an Amendment in the above-identified application.

- Small entity status of this application under 37 CFR §1.9 and §1.27 has been established by a verified statement previously submitted.
- A verified statement to establish small entity status under 37 CFR §1.9 and §1.27 is enclosed.
- No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	SMALL ENTITY	OTHER THAN SMALL ENTITY
CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO. PRE- VIOUSLY PAID FOR	PRESENT EXTRA		
TOTAL *33	-	** 64 =	0	
INDEP. * 6				
*** 6 =				
First presentation of multiple dependent claim				
	RATE	ADD'L FEE		
	x 9=	\$		
	x42=	\$		
	+140=	\$		
			OR	
	RATE	ADD'L FEE		
	x18=	\$		
	x84=	\$		
	+280=	\$		

TOTAL ADDITIONAL FEE \$0 OR \$ \_\_\_\_\_

- \* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- \*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- \*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

- Please charge my Deposit Account No. 13-3405 in the amount of \$ \_\_\_\_\_. A duplicate copy of this sheet is enclosed.
- A check in the amount of \$ \_\_\_\_\_ is attached.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 13-3405. A duplicate copy of this sheet is enclosed.
  - Any filing fees under 37 CFR §1.16 for the presentation of extra claims.
  - Any patent application processing fees under 37 CFR §1.17 with the exception of the Issue Fee which we intend to pay by check.

*TDC*  
T. Daniel Christenbury  
Reg. No. 31,750  
Attorney for Applicant(s)

TDC:dh  
(215)563-1810

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1644  
Examiner : R. Schwadron  
Serial No. : 09/155,514  
Filed : November 17, 1998  
Inventors : Mie Kainoh  
: Toshiaki Tanaka  
Title : CHIMERIC PROTEINS, THEIR  
: HETERODIMER COMPLEXES,  
: AND PLATELET SUBSTITUTES



22469

PATENT TRADEMARK OFFICE

Docket: 1102-98

Dated: January 14, 2002

AMENDMENT AND ARGUMENT

BOX AF  
Commissioner for Patents  
Washington, DC 20231

Sir:

In response to the Official Action dated August 15, 2001, Applicants amend as follows:

Marked-Up Version Showing Changes Made to the Claims

Kindly enter the following amendments:

2. (Twice Amended) A chimeric protein heterodimer complex, wherein a chimeric protein comprising an  $\alpha$  chain of an integrin and a heavy chain or light chain of an immunoglobulin and a chimeric protein comprising a  $\beta$  chain of an integrin and a heavy chain or light chain of an immunoglobulin are associated with each other.

24. (Twice Amended) A drug, comprising a chimeric protein as stated in any one of claims 45-49 or a chimeric protein heterodimer complex as stated in any claim 2 or claim 3.

46. (Amended) A chimeric protein comprising a  $\beta$  chain of an integrin and a heavy chain or light chain of an immunoglobulin, wherein said  $\beta$  chain of said integrin is selected from the group consisting of  $\beta_1$ ,  $\beta_2$ ,  $\beta_3$ ,  $\beta_4$ ,  $\beta_5$ ,  $\beta_6$ ,  $\beta_7$  and  $\beta_8$ .